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Abstract 
Unintended weight loss is a hallmark of Huntington disease (HD), but it is unknown to what extent 
weight loss impacts the rate of disease progression. Therefore, using longitudinal data from the Enroll-
HD study, we assessed the association between baseline body mass index (BMI) and the rate of clinical 
progression in 5821 HD mutation carriers. We found that high baseline BMI was associated with a 
significantly slower rate of functional, motor and cognitive deterioration (all p < 0.001), independent of 
mutant HTT CAG repeat size. Our findings provide strong rationale for exploration of systemic 
metabolism as a therapeutic target in HD. 
 
  
Introduction 
Huntington disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by a 
CAG repeat expansion in the HTT gene resulting in a long polyglutamine tract in the N-terminus of the 
encoded protein huntingtin.1 Apart from motor, cognitive and behavioral disturbances, a hallmark of the 
disease is unintended weight loss, both in HD patients and premanifest mutation carriers2,3 as well as 
various genetic animal models of the disease.4-6 Previously we found that weight loss in HD patients 
increases with larger mutant HTT CAG repeat size,2 while others reported higher caloric intake in 
premanifest mutation carriers with increasing CAG repeat length.7 These findings suggest a 
hypermetabolic state in HD which worsens with larger mutant HTT CAG repeat size, possibly due to a 
polyglutamine length-dependent interference of mutant huntingtin with cellular energy production.4  
Although in a small study higher body mass index (BMI) was found to be associated with slower disease 
progression,8 subsequent investigations in somewhat larger cohorts could not confirm this finding.9,10 
Therefore, despite resulting in general weakening and a decline in the quality of life,4 it is still unknown 
to what extent weight loss influences disease progression in HD. Elucidation of the association between 
body weight and disease progression, however, is of paramount importance as it would not only allow 
for a better prediction of disease course but could also provide a strong rationale for further exploration 
of promising energy-based treatments as potential therapeutic targets in HD.11,12 In this study, we 
therefore aimed to provide an accurate and conclusive estimate of the association between body weight 
and the rate of progression on the most important clinical domains of HD using longitudinal data from 
the largest cohort currently available.  
  
Materials and Methods 
Observational cohort study 
Participants: For assessing the association between BMI (defined as body weight in kilograms divided by 
the square of height in meters) and disease progression we used monitored data from 5821 individuals 
(54% female) participating in the Enroll-HD study, which also included longitudinal data from 2488 
individuals who had previously participated in the Registry study. 13,14 All participating sites were 
required to obtain and maintain local ethics committee approvals and all participants gave signed 
informed consent for their data to be included.13,14 We retrieved all data from the Enroll-HD website on 
February 17, 2017, and included all participants with a mutant CAG repeat size of ≥ 36 in our analysis.14  
 Statistical analyses 
We applied linear mixed-effects models with both fixed and random terms for disease duration to 
account for the correlation between the repeated measurements on each individual, using an 
unstructured variance-covariance matrix.15 First, we assessed the rate of weight loss by including BMI as 
the dependent variable and sex, age of onset (defined as the age at clinical diagnosis), disease duration 
and mutant CAG repeat size as independent variables. Next, we also included an interaction term 
between disease duration and mutant CAG repeat size to quantify the effect of CAG repeat size on the 
rate of weight loss. Subsequently, we assessed the effect of baseline BMI ─ defined as the first BMI 
measurement recorded for each subject ─ on measures of disease progression including Unified 
Huntington Disease Rating Scale (UHDRS) total functional capacity (TFC), total motor score (TMS) and all 
available UHDRS cognitive sub-scores. In addition, we performed a principal components analysis on the 
six UHDRS cognitive subdomains to derive a unique summary statistic which could capture most of the 
variation in the cognitive scores: This analysis resulted in six factors of which the first (principal 
component 1 (PC1)) accounted for 80.9% of the variation, while the other factors each accounted for 
6.5% or less of the variation. Therefore, we also used PC1 as a dependent variable. Each measure of 
disease progression was treated as the dependent variable while disease duration, baseline BMI as well 
as its interaction with disease duration, sex, age of onset, mutant CAG repeat size and its interaction 
with disease duration were included as independent variables. For subgroup analyses, we divided the 
cohort based on baseline BMI in underweight, normal weight, overweight, obese and morbidly obese 
individuals according to the World Health Organization cut-off points of <18.5, 18.5-<25, 25-<30, 30-<40 
and ≥ 40 kg/m2, respectively. To reduce multicollinearity all continuous variables were centered around 
their respective means. All values are reported as mean ± standard deviation unless otherwise specified. 
All tests were two-tailed and the threshold for statistical significance was set at 0.05. Programming was 
performed in RStudio Version 1.0.136 (R base 3.3.2) using the ‘lme4’ package. 
 
Results 
Weight loss in HD patients 
At baseline, BMI ranged from 11.7 to 63.2 kg/m2 (median: 24.7 kg/m2, interquartile range: 22.0 to 28.1 
kg/m2). Mean baseline BMI was 25.6 ± 5.2 kg/m2 and average BMI declined with 0.06 units (95% CI: -
0.08 to -0.03, p < 0.001) per year. For each extra CAG repeat average BMI was 0.32 units lower (95% CI: 
-0.38 to -0.26, p < 0.001) and the rate of weight loss aggravated with 0.02 BMI units/year (95% CI: -0.03 
to -0.01, p < 0.001), after adjustment for sex, age of onset and disease duration (Figure 1).  
Baseline BMI is a significant predictor of disease progression 
Mean baseline TFC score was 9.9 ± 3.4, decreasing by 0.53 points per year (95% CI: -0.51 to -0.55). Each 
unit increase of baseline BMI was associated with 0.012 points/year slower decline on the TFC scale 
(95% CI: 0.008 to 0.016, p < 0.001), Figure 2A.  
The average TMS score at baseline was 24.7 ± 21.4, increasing by 3.25 point per year (95% CI: 3.14 to 
3.36). Each unit increase in baseline BMI was related to 0.059 points/year slower rate of deterioration 
on the TMS scale (95% CI: -0.080 to -0.037, p < 0.001), Figure 2B.  
As expected all UHDRS cognitive sub-scores significantly deteriorated during the follow-up period (Table 
1). Higher baseline BMI was associated with a slower rate of decline on all UHDRS cognitive subdomains 
as well as the cognitive summary score represented by PC1 (Table 1 and Figure 2C).   
Sensitivity and subgroup analyses 
Given that our primary analyses were based on the entire dataset which also contained individuals with 
underweight (n=203) or morbid obesity (n=96) (Figures 1 and 2) we also performed a sensitivity analysis 
by repeating the calculations after exclusion of these individuals. The results did not change materially 
and remained statistically significant (data not shown). Similarly, adjustment for disease stage at 
baseline, as represented by the TFC score, did not change the statistical significance of the results (data 
not shown). Compared to normal weight participants and after adjustment for sex, age of onset, disease 
duration and CAG repeat size: 1) In underweight individuals mean TFC score was lower and mean TMS 
score was higher by 1.12 and 7.82 points, respectively (both p<0.001), 2) In overweight, obese and 
morbidly obese individuals mean TMS scores were lower by 2.29, 4.36 and 7.04 points, respectively (all 
p<0.01), and 3) the rates of functional and motor deterioration were significantly slower in (morbidly) 
obese individuals, while the rate of cognitive deterioration was slower in overweight and obese 
participants (all p<0.01).   
 
Discussion 
Using high-quality, longitudinal data from the largest cohort of HD mutation carriers available to date, 
here we present conclusive evidence for an association between body weight and the rate of disease 
progression in HD. Patients with a high BMI at baseline exhibited a slower rate of progression on all 
clinical domains which are known to deteriorate with longer disease duration in HD, including functional 
capacity, motor function and cognitive performance. In addition, we provide more precise estimates of 
the strong length-dependent detrimental effect of mutant HTT CAG repeat size on body weight and the 
rate of weight loss, validating and extending our previous findings.2 Importantly, however, the 
association between BMI and disease progression was independent of mutant CAG repeat size, 
indicating that factors other than CAG repeat size must account for this relation.  
Until now reports regarding a possible link between body weight and disease progression in HD have 
been discrepant. Although Myers et al. were the first to identify a high BMI as a predictor of slower 
progression in a group of 42 patients with HD,8 it is unknown to what extent baseline differences in 
mutant HTT CAG repeat size, which is strongly associated with both BMI and disease progression,2 might 
have accounted for their findings. Moreover, subsequent studies found no clear association between 
body weight and disease progression.9,10 However, unequivocal interpretation of these previous reports 
is further limited by the fact that most of them involved relatively small-scaled studies which were 
performed before the introduction of the UHDRS, a rating scale which standardized clinical assessment 
in HD and thereby allowed for a more accurate evaluation of disease progression.16 Taking advantage of 
a much larger cohort of HD mutation carriers who were systematically and uniformly followed up for a 
considerable amount of time, here we show that a relatively high BMI is indeed a robust and consistent 
predictor of disease progression in HD. Importantly, the effect of BMI was seen on all clinical measures 
of progression in HD including functional and motor impairment and decline on all cognitive sub-
domains of the UHDRS.  As the mechanisms governing the rate of motor and cognitive decline in HD are 
likely to be central, it is tempting to speculate that the association between BMI and disease progression 
in HD might be due to an effect of disturbances of energy regulating mechanisms on central nervous 
system function.4 Dysregulation of energy homeostasis in HD could be mediated through pathology of 
central energy regulating structures, especially the hypothalamus which is known to be affected in 
HD,17,18 or might arise from cellular alterations engendered by mutant huntingtin expression in 
peripheral tissues.19  
Our study has certain limitations. First, although our findings indicate that BMI is a strong predictor of 
disease progression in HD, the observational nature of our study does not permit for direct conclusions 
regarding the directionality or causality of this association. Second, data on body composition were not 
collected, precluding a further characterization of which body weight components (i.e. fat-free or fat 
mass) mediate the largest effect.20  
In conclusion, we found that a high BMI was associated with a slower rate of disease progression in HD 
independent of mutant HTT CAG repeat size and disease stage. These findings thus suggest that 
systemic metabolism could influence clinical progression in HD, and should therefore be further 
explored as a potential target area for therapeutic interventions aiming to modify the rate of 
progression of HD.     
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Figure legends: 
 
Figure 1: Weight loss increases with higher CAG repeat size. The graph depicts the relation between 
BMI and age with separate regression lines for each category of mutant HTT CAG repeat size. It is 
evident from this graph that patients with higher CAG repeat size have both a lower body weight and a 
higher rate of weight loss. The shaded areas around the regression lines indicate the 95% confidence 
intervals around the estimates. Median follow-up time was 2.0 years (interquartile range: 0.9 to 3.7). 
Mutant CAG repeat size ranged from 36 to 67 (mean ± standard deviation: 43.4 ± 3.5). Inset: Colors 
represent different categories of CAG repeats based on the indicated cut-off values (note that the first 
category in red represents carriers of mutations in the reduced-penetrance range).  
 
Figure 2. Higher baseline BMI is associated with slower disease progression in Huntington disease. A 
higher body mass index (BMI) at baseline was associated with a slower rate of progression on all 
assessed clinical domains in patients with Huntington disease, including total functional capacity (A), 
total motor score (B) and a cognitive summary score represented by PC1 (C, please refer to the text for 
details). All estimates were adjusted for sex, age of onset and mutant CAG repeat size. Each point 
represents one subject and the shaded areas around the regression lines indicate the 95% confidence 
intervals around the estimates. 
 
  
Table 1: Effect of baseline body mass index on measures of disease progression in Huntington disease. 
Legend: *p<0.05, **p<0.01, ***p<0.001   
1) This column contains the regression coefficients associated with disease duration which can be 
interpreted as the rate of disease progression per year in units of the particular outcome measure.   
2) This column contains the regression coefficients associated with baseline BMI which can be 
interpreted as the average increase or decrease in the outcome measure during the follow-up period 
per unit increase of baseline BMI. 
3) This column contains the regression coefficients of the interaction term between baseline BMI and 
disease duration: A significant interaction means that baseline BMI affects the rate of disease 
progression. 
4) All Unified Huntington Disease Rating Scale cognitive scores indicate the total number of correct items 
(in 1 minute) 
5) The first principal component (PC1) of a principal component analysis based on all six Unified 
Huntington Disease Rating Scale cognitive scores (please refer to the main text for further details).  
 
 Disease duration1 BMI baseline2 Interaction3 
Total Functional Capacity -0.53 (-0.55, -0.51) *** 0.017 (-0.002, 0.036) 0.012 (0.008, 0.016) *** 
Total Motor Score 3.25 (3.14, 3.36) *** -0.498 (-0.606, -0.390) *** -0.059 (-0.080, -0.037) *** 
Symbol Digit Modality Test4 -1.43 (-1.49, -1.37) *** 0.265 (0.192, 0.338) *** 0.023 (0.011, 0.036) *** 
Stroop Color Naming Test4 -1.98 (-2.08, -1.88) *** 0.208 (0.104, 0.312) *** 0.046 (0.026, 0.067) *** 
Stroop Word Reading Test4 -2.91 (-3.05, -2.78) *** 0.148 (0.017, 0.280) * 0.058 (0.031, 0.085) *** 
Stroop Interference Test4 -1.09 (-1.16, -1.02)*** 0.093 (0.023, 0.162) ** 0.029 (0.015, 0.042) *** 
Verbal Fluency Test (Categories)4 -0.53 (-0.57, -0.50) *** 0.067 (0.037, 0.099) *** 0.011 (0.005, 0.018) *** 
Verbal Fluency Test (Letters) 4 -0.67 (-0.75, -0.60) *** 0.181 (0.096, 0.266) *** 0.022 (0.007, 0.037) ** 
Cognitive Summary Score (PC1)5 -0.19 (-0.20, -0.18) *** 0.019 (0.007, 0.030) ** 0.004 (0.002, 0.006) *** 
